Explore

Trendline Trendline
UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies
Trendline Trendline
UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers
Trendline Trendline
UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline

UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline

UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline
Trendline Trendline
UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal

UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal

UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal
Trendline Trendline
UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with T-cell Engagers
Trendline Trendline
UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline with T-cell Engagers

UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline with T-cell Engagers

UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline with T-cell Engagers
Trendline Trendline
Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market
Reuters Reuters
Pfizer pins post 2028 return to growth on new obesity and cancer drugs

Pfizer pins post 2028 return to growth on new obesity and cancer drugs

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth after 2028, driven by obesity drugs in development, a patent extension for its heart drug Vyndamax and a favorable European court ruling on its COVID-19 vaccine.
Trendline Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables
Trendline Trendline
Schrödinger to Engage Investors at May 2026 Conferences

Schrödinger to Engage Investors at May 2026 Conferences

Schrödinger to Engage Investors at May 2026 Conferences
Trendline Trendline
Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks

Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks

Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks
Trendline Trendline
Big Tech Companies Innovate Drug Discovery with AI Platforms

Big Tech Companies Innovate Drug Discovery with AI Platforms

Big Tech Companies Innovate Drug Discovery with AI Platforms